GPC3 Assay Portfolio Service
With unrivaled expertise and experience in various immunotherapy discovery and development, Creative Biolabs is confident in providing an integrated solution for GPC3 assay services to best suit your program requirements.
Tumor Target GPC3
GPC3 (Glypican-3, also known as OCI-5, MXR7) is an oncofetal heparan sulfate (HS) glycoprotein that is attached to the cell membrane by glycosylphosphatidylinositol (GPI). GPC3 is expressed in embryonic tissues widely, including lung, liver and kidneys, while absent in adult tissues. GPC3 could interact with several receptors and ligands, such as cell adhesion molecules, extracellular matrix components, growth factors, and enzymes. It is reported that GPC3 plays a crucial role in multiple signaling pathways, such as Wnt, hedgehog, bone morphogenic protein, and FGF pathways, regulating cell growth and apoptosis in certain cell types.
Fig.1 Structure of the glypican-3 (GPC3) molecule and involvement in the progression of HCC. (Nishida, 2019)
GPC3-Targeted Therapies
GPC3, as a novel tumor marker for HCC, is closely involved in the prognosis of hepatocellular carcinoma. Additionally, GPC3 is also related to various cancers (such as melanoma, non-small cell lung cancer, ovarian clear cell carcinoma, colon cancer), and is expressed in tumor tissues differentially.
Currently, there are multiple therapeutic strategies targeting GPC3, including vaccines, antibodies, antibody-drug conjugates, and CAR-T therapies. Some of these approaches have entered clinical trials, including the representative GPC3 humanized monoclonal antibody GC33, TRAB (ERY974), GPC3-peptide vaccine and Anti-GPC3 CAR-T therapies.
Fig.2 GPC3-targeted immunotherapies. (Nishida, 2019)
Our GPC3 Assay Portfolio Services
To speed up the development of GPC3-targeted therapies, Creative Biolabs is dedicated to providing one-stop GPC3 assay portfolio services to help our clients meet the program requirements. Equipped with state-of-the-art facilities and experienced immune-oncology experts, we can provide services covering the initial target validation in vitro to the later preclinical analysis to meet the requirements of scientific research.
Our Capabilities
-
We offer pre-validated assay panels for GPC3.
-
We offer various fast, reliable and most cost-effective analysis methods in GPC3 assay service to fulfill your needs.
-
We customize assay services according to your needs.
For more details of our GPC3 assay portfolio services, please don’t hesitate to contact us for more information.
Reference
-
Nishida, T.; Kataoka, H. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers. 2019, 11(9): 1339.
For Research Use Only | Not For Clinical Use
Download our brochure